In Depth 19 Sep 2024
Mitochondrial disease treatments: is a breakthrough on the horizon?
Mitochondrial dysfunction is linked to many diseases. Discover how biotechs are developing mitochondrial disease treatments to address these diseases.
mitochondria
- Latest Posts
News and Trends 23 Mar 2023
Intracellular “smoke detector” discovery has skin disease therapy implications
A study by the University of Bonn in Germany could lead to therapies against skin and intestinal diseases in the medium term.Researchers at the universities of Bonn and Singapore have discovered a new intracellular “smoke detector.” The sensor warns of damage to the mitochondria – the microscopic power plants that supply the cell with energy. […]
News and Trends 7 Feb 2023
Harvard spin-off cellvie closes $5.5M new funding
cellvie Inc., which works on therapeutic mitochondria transplantation (TMT), an approach developed at Harvard Medical School, has closed a $5.5 million financing to get Series A-ready by the end of 2023. Mitochondria dysfunction has been tied to a host of diseases, ranging from neurodegenerative ailments, heart attacks and strokes, to age-related degeneration. “Whilst mitochondria have […]
News and Trends 2 Dec 2022
Khondrion’s sonlicromanol produces encouraging results for next stage of study
Biopharma company, Khondrion, has marked announced improvements from patients with MELAS spectrum disorders taking its lead asset, sonlicromanol. Updates were provided by the company from a 28-day double-blind, randomized placebo-controlled, three-way cross-over phase 2b study called KHNERGYZE in which 27 took part. It also reported updates on the ongoing, open-label extension KHEREREXT phase 2b study […]
News and Trends 23 Nov 2022
Khondrion’s mitochondrial diseases treatment producing positive results
Clinical-stage pharmaceutical company, Khondrion, discovering and developing therapies targeting primary mitochondrial diseases announced yesterday (November 22) its wholly-owned lead asset sonlicromanol for MELAS spectrum disorder has demonstrated positive treatment results. MELAS spectrum disorder is a rare progressive mitochondrial disease and sonlicromanol will move into a phase 3 registrational study supported by favorable benefit-risk profile. The […]
News and Trends 30 Jun 2022
NRG Therapeutics selects Domainex for project aimed at finding candidate for neurogenerative disorders
A neuroscience company targeting mitochondrial dysfunction has teamed up with an organization developing small molecule disease-modifying medicines for the treatment for chronic neurogenerative disorders. Domainex, an integrated medicines research services partner has been chosen by neuroscience company, NRG Therapeutics, and will be providing fully integrated lead optimization services including assay biology and medicinal computational chemistry. […]
ADVERTISEMENT
ADVERTISEMENT
News and Trends 6 Jun 2022
Mitochondria in focus as 4BIO Capital co-leads $30.3M financing in LUCA Science
4BIO Capital, an international venture capital firm focusing on the advanced therapies sector, has co-led a $30.3M oversubscribed Series B financing in LUCA Science Inc., which is developing a novel class of mitochondria biopharmaceutical agents. The round was co-led with DCI Partners and existing investor Fast Track Initiative, and supported by existing international investors including […]
ADVERTISEMENT